Table 3 Results from positive Phase 3 clinical trials used in first-line therapy studiesres
From: Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy
Phase 3 clinical trials | IMBRAVE 150 | HIMALAYA | Checkmate 9DW | |||
|---|---|---|---|---|---|---|
Treatment | Atezolizumab–Bevacizumab | Sorafenib | Durvalumab–Tremelimumab | Sorafenib | Nivolumab–Ipilimumab | Sorafenib |
Overall survival (median) months | 19.2 | 13.2 | 16.4 | 13.8 | 23.7 | 20.6 |
Overall survival rate at 24 months | - | - | 40.5% | 32.6% | 19% | 39% |
Overall survival rate at 36 months | - | - | 30.7% | 19.8% | 38% | 24% |
Overall survival rate at 48 months | - | - | 25.2% | 15.1% | - | - |
Disease-free survival (median) months | 6.8 | 4.3 | 3.8 | 4.1 | 9.1 | 9.2 |
Objective response rate | 30% | 11% | 20% | 5% | 36% | 13% |
